,i  #aaf? ,,congress  #a/ ,session  ,h4 
,r4 #bcgf  ,,9 ,,! ,,h\se ,,(           
,,repres5tatives  ,april #bi1 #bjai,mr4 
,coll9s ( ,georgia 7= himself & ,mr4    
,nadl]7 introduc$ ! foll[+ bill2 :i* 0  
ref]r$ to ! ,committee on ,en]gy &      
,comm]ce1 & 9 addition to ! ,committee  
on ! ,judici>y1 = a p]iod to be         
subsequ5tly det]m9$ by ! ,speak]1 9 ea* 
case = consid]ation ( su* provisions z  
fall )9 ! jurisdiction ( ! committee    
conc]n$  ,a ,,bill  ,to require ! ,f$]al
 ,trade ,commission to /udy ! role (    
int]m$i>ies 9 ! ph>maceutical supply *a9
 & provide ,congress ) appropriate      
policy recomm5dations1 & = o!r purposes4
  #a4 ,%ort title ,?is ,act may be cit$ 
z ! ,prescription ,pric+ = ! ,p ,act (  
#bjai4  #b4 ,def9itions ,9 ?is ,act3    
7#a7 ,appropriate committees ( congress 
,! t]m appropriate committees (         
,congress means-- 7,a7 ! ,committee on !
 ,judici>y ( ! ,s5ate2 &  7,b7 !        
,committee on ! ,judici>y ( ! ,h\se (   
,repres5tatives4  7#b7 ,commission ,!   

t]m ,commission means ! ,f$]al ,trade   
,commission4  #c4 ,/udy ( ph>maceutical 
supply *a9 int]m$i>ies & m]g] activity  
7a7 ,initial report ,n lat] ?an #a ye>  
aft] ! date ( enactm5t ( ?is ,act1 !    
,commission %all submit to ! appropriate
 committees ( ,congress a report t--    
7#a7 addresses at m9imum-- 7,a7 :e!r    
ph>macy b5efit manag]s--  7i7 *>ge pay]s
 a high] price ?an ! reimbursem5t rate  
at :i* ! ph>macy b5efit manag]s         
reimburse compet+ ph>macies2  7ii7 /e]  
pati5ts = anticompetitive purposes to   
any ph>macies1 includ+ retail1          
mail-ord]1 or any o!r type ( ph>macy1 9 
:i* ! ,,pbm has an own]%ip int]e/2      
7iii7 audit or review propriet>y data1  
includ+ acquisition co/s1 pati5t        
in=mation1 or disp5s+ in=mation1 (      
compet+ ph>macies t c be us$ =          
anticompetitive purposes2 or  7iv7 use  
=mul>y designs to increase ! m>ket %>e (
 high] co/ prescription drugs & depress 
! m>ket %>e ( l[] co/ prescription drugs
 7ea* net ( rebates & disc\nts72  7,b7  

:e!r !re are any specific legal or      
regulatory ob/acles ! ,commission       
curr5tly faces 9 ensur+ a competitive & 
transp>5t m>ketplace 9 ! ph>maceutical  
supply *a91 includ+ ! ph>macy b5efit    
manag] m>ketplace & ph>macy s]vices     
adm9i/rative organizations2  7,c7 h[    
companies & pay]s assess ! b5efits1     
co/s1 & risks ( contract+ ) int]m$i>ies1
 includ+ ph>macy s]vices adm9i/rative   
organizations1 & :e!r m in=mation ab\t !
 roles ( int]m$i>ies %\ld be available  
to consum]s & pay]s2 &  7,d7 :e!r !re   
are any specific legal or regulatory    
ob/acles ! ,commission curr5tly faces 9 
ensur+ a competitive & transp>5t        
m>ketplace 9 ! ph>maceutical supply *a91
 includ+ ! ph>macy b5efit manag]        
m>ketplace & ph>macy s]vices            
adm9i/rative organizations2 &  7#b7     
provides-- 7,a7 obs]vations or          
conclusions drawn f ! ,novemb] #bjag    
r\ndtable entitl$ ,und]/&+ ,competition 
9 ,prescription ,drug ,m>kets3 ,entry & 
,supply ,*a9 ,dynamics1 & any simil>    

ef=ts2  7,b7 specific actions !         
,commission int5ds to take z a result ( 
! ,novemb] #bjag r\ndtable1 & any simil>
 ef=ts1 includ+ a detail$ description ( 
relevant =?com+ actions1 additional     
rese>* or r\ndtable discussions1 consum]
 education ef=ts1 or en=cem5t actions2 &
  7,c7 policy or legislative            
recomm5dations to-- 7i7 improve         
transp>5cy & competition 9 !            
ph>maceutical supply *a92  7ii7 prev5t &
 det] anticompetitive behavior 9 !      
ph>maceutical supply *a92 &  7iii7 be/  
ensure t consum]s b5efit f any co/ sav+s
 or effici5cies t may result f m]g]s &  
consolidations4  7b7 ,int]im report ,n  
lat] ?an #ahj days aft] ! date (        
enactm5t ( ?is ,act1 ! ,commission %all 
submit to ! appropriate committees (    
,congress an int]im report on ! progress
 ( ! report requir$ by subsection 7a71  
along ) prelim9>y f9d+s & conclusions   
bas$ on in=mation collect$ to t date4